Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$6.12
-0.0901-1.45%
Last update: Dec 15, 11:20 AM
Comments
Loading...
Aquestive Therapeutics (AQST) Stock Price, Quote, News & History
AQSTNASDAQ
Edge Rankings
Stock Score Locked: Want to See it?
Benzinga Rankings give you vital metrics on any stock – anytime.
Compare
EPS worse than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
EPS worse than industry
FAQ
How do I buy Aquestive Therapeutics (AQST) stock?
You can purchase shares of Aquestive Therapeutics (NASDAQ:AQST) through any online brokerage.
Who are Aquestive Therapeutics (AQST) competitors?
Other companies in Aquestive Therapeutics’s space includes: Zevra Therapeutics Inc (NASDAQ:ZVRA), Theravance Biopharma Inc (NASDAQ:TBPH), GH Research PLC (NASDAQ:GHRS), SNDL Inc (NASDAQ:SNDL) and Bioage Labs Inc (NASDAQ:BIOA).
What is the forecast, or price target, for Aquestive Therapeutics (AQST) stock?
Aquestive Therapeutics has a consensus price target of $9.90.
What is the current price for Aquestive Therapeutics (AQST)?
The stock price for Aquestive Therapeutics (NASDAQ: AQST) is $6.1199 last updated December 15, 2025 at 11:20 AM EST.
Does Aquestive Therapeutics (AQST) pay a dividend?
There are no upcoming dividends for Aquestive Therapeutics.
When is Aquestive Therapeutics (NASDAQ:AQST) reporting earnings?
Aquestive Therapeutics does not have any upcoming earnings scheduled.
Is Aquestive Therapeutics (AQST) going to split?
There is no upcoming split for Aquestive Therapeutics.
What sector and industry does Aquestive Therapeutics (AQST) operate in?
Aquestive Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
